Main content area

Development of Nanoscale Oil Bodies for Targeted Treatment of Lung Cancer

Chiang, Chung-Jen, Lin, Li-Jen, Wu, Chia-Pei, Chen, Chih-Jung, Chao, Yun-Peng
Journal of agricultural and food chemistry 2018 v.66 no.36 pp. 9438-9445
Escherichia coli, antineoplastic activity, antineoplastic agents, epidermal growth factor receptors, hydrophobicity, lipid bodies, lung neoplasms, neoplasm cells, oleosin, phospholipids, plant fats and oils, therapeutics
Lung cancer is the most widespread disease and is frequently associated with a high level of epidermal growth factor receptor (EGFR). This study was thus conducted to provide a proof-of-concept approach for targeted therapy of lung cancer by development of nanoscale oil bodies (NOBs). This was carried out by fusion of anti-EGFR affibody (ZEGFR₂) with oleosin (Ole), a structure protein of plant seed oils. The fusion protein (Ole-ZEGFR₂) was produced in Escherichia coli. NOBs were spontaneously assembled from plant oil, phospholipids, and Ole-ZEGFR₂. Consequently, Ole-ZEGFR₂-based NOBs were selectively internalized by EGFR-positive lung cancer cells with an efficiency exceeding 90%. Furthermore, the hydrophobic anticancer drug, camptothecin (CPT), was encapsulated into Ole-ZEGFR₂-based NOBs. The administration of the CPT formulation based on NOBs resulted in a strong antitumor activity both in vitro and in vivo.